Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC in Locally Advanced Cutaneous Angiosarcoma
NCT03921073Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2019
- Primary completion
- Sep 2021
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of talimogene laherparepvec in cutaneous angiosarcoma (cAS), sponsored by Moffitt Cancer Center. Started Aug 2019; status: terminated.
02
Drugs
talimogene laherparepvec
03
Conditions
cutaneous angiosarcoma (cAS)
Beyond the preview
Go deeper on NCT03921073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921073.